ASSOCIATION OF POLYCYSTIC OVARY SYNDROME AND THYROID DYSFUNCTION AMONG REPRODUCTIVE WOMEN: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i2.48788Keywords:
Follicle-stimulating hormone, Hypothyroidism, Polycystic ovarian syndrome, Luteinizing hormoneAbstract
Objective: Polycystic ovarian syndrome (PCOS) is became most common problem in the reproductive age group women who seem to be adversely affected by associated thyroid dysfunction. Ovarian failure and pregnancy-related complications leaded by both factors. The study helps to explore the incidence and etiology of diverse thyroid conditions among PCOS individuals.
Methods: This prospective single‑center study with 40 female patients with hyperandrogenism, hirsutism, oligo‐anovulation, and polycystic ovaries patients were defined as having PCOS according to the revised 2003 Rotterdam criteria and Ferriman–Gallwey score with comprised the study population. Normal female subjects were studied as the control population who had normal thyroid function and without PCOS. By measuring of serum thyroid-stimulating hormone (TSH), free thyroxine levels (free T3 and free T4), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen, progesterone, and testosterone can evaluate thyroid function. Along with ultrasound was performed to confirm the PCOS. By SPSS version 19 Chi-square test and t-test were determined.
Results: This case–control study revealed that a statistically significant higher prevalence of PCOS patients was found to have higher mean TSH values that were 5.33±2.51 μIU/mL, the mean for T3 and T4 was 154±138 μg/dL and 11.27±8.47 μg/dL, respectively. The mean FSH values were 07.27±4.49 μIU/mL, the mean LH was 84.27±38.49 μIU/mL, the mean estrogen 342±202 pg/mL, the mean progesterone values were 14.2±8.9 ng/mL and the mean testosterone levels were 69.73±9.28 ng/mL.
Conclusion: Thyroid dysfunction shows a high prevalence in PCOS patients. Dysfunction can be treated which helps to manage infertility associated with PCOS.
Downloads
References
Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800. doi: 10.1210/edrv.18.6.0318
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9. doi: 10.1210/jcem.84.1.5393
Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-9. doi: 10.1530/ eje.0.1500363
Balen AH, Anderson RA, Policy and Practice Committee of the BFS. Impact of obesity on female reproductive health: British Fertility Society, Policy and Practice Guidelines. Hum Fertil (Camb) 2007;10:195-206. doi: 10.1080/14647270701731290
Dewailly D, Hieronimus S, Mirakian P, Hugues JN. Polycystic ovary syndrome (PCOS). Ann Endocrinol (Paris) 2010;71:8-13. doi: 10.1016/j.ando.2009.12.003
Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7. doi: 10.1210/jcem- 21-11-1440
Carmina E, Lobo RA. A comparison of the relative efficacy of anti-androgens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002;57:231-4. doi: 10.1046/j.1365-2265.2002.01594.x
Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003;79:91-5. doi: 10.1016/s0015-0282(02)04551-x
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009;91:456-88. doi: 10.1016/j. fertnstert.2008.06.035
Najem F, Elmehdawi R, Swalem A. Clinical and biochemical characteristics of polycystic ovary syndrome in Benghazi-Libya; a retrospective study. Libyan J Med 2008;3:71-4. doi: 10.4176/080122
Amato MC, Galluzzo A, Merlino S, Mattina A, Richiusa P, Criscimanna A, et al. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. Eur J Endocrinol 2006;155:859-65. doi: 10.1016/j.fertnstert.2008.06.021
Huang J, Ni R, Chen X, Huang L, Mo Y, Yang D. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. Reprod Biol Endocrinol 2010;17:8-14. doi: 10.1186/1477-7827- 8-142
Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo-and hyperinsulinemia. Rocz Akad Med Bialymst 2003;48:131- 4. PMID: 14737959
Anlakash AH. Polycystic ovarian syndrome-the correlation between LH/FSH ratio and disease manifestation. Middle East Fertil Soc Jl 2007;12:35-40. doi: 10.5455/medarh.2020.74.289-293
Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2012;285:853-6. doi: 10.1007/s00404-011-2040-5
Wakim AN, Polizotto SL, Burholt DR. Augmentation by thyroxine of human granulosa cell gonadotrophin-induced steroidogenesis. Hum Reprod 1995;10:2845-8. doi: 10.1093/oxfordjournals.humrep.a135805
Ozdemir D, Cuhaci N, Balkan F, Usluogullari A, Ersoy R, Cakir B. Prevalence of thyroid pathologies in patients with polycystic ovary syndrome. Eur Cong Endocrinol 2011;26:92.
Ghosh S, Kabir SN, Pakrashi A, Chatterjee S, Chakravarty B. Subclinical hypothyroidism: A determinant of polycystic ovary syndrome. Horm Res 1993;39: 61-6.
Published
How to Cite
Issue
Section
Copyright (c) 2023 V Anebaracy , Kumaran, C Rekha , A Karuppiah Pandi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
